Asset Details
Do you wish to reserve the book?
STEPS: Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
STEPS: Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease
Do you wish to request the book?
STEPS: Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
STEPS: Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease
2018
Overview
Lifitegrast ophthalmic solution 5% (Xiidra) is labeled for the treatment of dry eye disease, also known as keratoconjunctivitis sicca.1 It is an inhibitor of the lymphocyte function-associated antigen 1 (LFA-1) and has been shown to reduce immune-mediated inflammation.1 Drug Dosage Dose form Cost* Lifitegrast ophthalmic solution 5% (Xiidra) One drop in each eye every 12 hours Single-use ampule of 5% solution $527 *-Estimated retail price of one month's treatment based on information obtained at http://www.goodrx.com (accessed June 4, 2018). Safety No serious adverse effects have been reported with the use of lifitegrast in clinical trials of up to one year in duration.2 Lifitegrast is not systemically detectable despite long-term administration, making systemic effects unlikely.1,2 The medication has not been studied in women who are pregnant or breastfeeding, children, or adolescents.1 Tolerability Approximately one in eight patients will discontinue lifitegrast therapy because of adverse effects.2 The most common adverse effects are altered taste (16.2%), eye irritation or burning (15%), and visual acuity reduction (11.4%).2 Effectiveness Lifitegrast has been evaluated in four 12-week randomized controlled trials involving a total of 2,132 patients.3 Patients receiving lifitegrast initially had moderate symptoms, an average score of 40 to 70 on a scale of 0 to 100, and some corneal lesions on fluorescein stain.3 Patients who received lifitegrast experienced a small reduction in symptoms (an average of 14 to 38 points), although these scores were only five to 12 points better than with placebo.3 Corneal lesions improved at a rate similar to that of placebo. Bottom Line Studies have shown that lifitegrast will reduce the symptoms of dry eye disease in some patients, although the benefit is borderline clinically significant.
Publisher
American Academy of Family Physicians
Subject
